Immunic Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.52
- Today's High:
- $1.5857
- Open Price:
- $1.52
- 52W Low:
- $1.11
- 52W High:
- $11.76
- Prev. Close:
- $1.53
- Volume:
- 155928
Company Statistics
- Market Cap.:
- $76.70 million
- Book Value:
- 1.557
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -53.18%
- Return on Equity TTM:
- -128.82%
Company Profile
Immunic Inc had its IPO on 2014-04-17 under the ticker symbol IMUX.
The company operates in the Healthcare sector and Biotechnology industry. Immunic Inc has a staff strength of 75 employees.
Stock update
Shares of Immunic Inc opened at $1.52 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.52 - $1.59, and closed at $1.52.
This is a -0.65% slip from the previous day's closing price.
A total volume of 155,928 shares were traded at the close of the day’s session.
In the last one week, shares of Immunic Inc have slipped by -11.63%.
Immunic Inc's Key Ratios
Immunic Inc has a market cap of $76.70 million, indicating a price to book ratio of 0.4258 and a price to sales ratio of 0.
In the last 12-months Immunic Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-96655000. The EBITDA ratio measures Immunic Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Immunic Inc’s operating margin was 0% while its return on assets stood at -53.18% with a return of equity of -128.82%.
In Q2, Immunic Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Immunic Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-3.55 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Immunic Inc’s profitability.
Immunic Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.3018. Its price to sales ratio in the trailing 12-months stood at 0.
Immunic Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $88.74 million
- Total Liabilities
- $18.24 million
- Operating Cash Flow
- $4.34 million
- Capital Expenditure
- $21000
- Dividend Payout Ratio
- 0%
Immunic Inc ended 2024 with $88.74 million in total assets and $0 in total liabilities. Its intangible assets were valued at $88.74 million while shareholder equity stood at $69.28 million.
Immunic Inc ended 2024 with $0 in deferred long-term liabilities, $18.24 million in other current liabilities, 4000.00 in common stock, $-366551000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $77.29 million and cash and short-term investments were $77.29 million. The company’s total short-term debt was $671,000 while long-term debt stood at $0.
Immunic Inc’s total current assets stands at $86.55 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $4.06 million compared to accounts payable of $4.35 million and inventory worth $3.81 million.
In 2024, Immunic Inc's operating cash flow was $4.34 million while its capital expenditure stood at $21000.
Comparatively, Immunic Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.52
- 52-Week High
- $11.76
- 52-Week Low
- $1.11
- Analyst Target Price
- $13.25
Immunic Inc stock is currently trading at $1.52 per share. It touched a 52-week high of $11.76 and a 52-week low of $11.76. Analysts tracking the stock have a 12-month average target price of $13.25.
Its 50-day moving average was $2.05 and 200-day moving average was $1.77 The short ratio stood at 2.97 indicating a short percent outstanding of 0%.
Around 1539.7% of the company’s stock are held by insiders while 5594.5% are held by institutions.
Frequently Asked Questions About Immunic Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 3 clinical for treatment of multiple sclerosis, including relapsing multiple sclerosis and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.